Publications
5491 Results
- Journal / Conference
- WCLC Annual Meeting (September 9-12, 2023, Singapore), poster
- Year
- 2023
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- Study Number(s)
- S1609
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Bronchoalveolar Carcinoma of the Lung (Cohort 12)
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 4; abstr LBA490); ASCO GI Cancers Symposium (January 19-21, 2023, San Francisco, CA), oral
- Year
- 2023
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- S1815
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers (SWOG S1815; NCT#03768414)
- Journal / Conference
- AACR Annual Meeting (April 14-19, 2023, Orlando, FL, poster
- Year
- 2023
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- Study Number(s)
- S1609
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The non-epithelial ovarian tumor cohort #13
- Journal / Conference
- AACR Annual Meeting (April 14-19, 2023, Orlando, FL, poster
- Year
- 2023
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- Study Number(s)
- S1609
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The small cell carcinoma of the ovary, hypercalcemic type cohort #49
- Journal / Conference
- Annals of Oncology VOLUME 34, SUPPLEMENT 2, S1015; ESMO (October 20-24, 2023, Madrid, Spain), poster
- Year
- 2023
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S0931
Adjuvant everolimus in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: results from the phase III placebo-controlled SWOG S0931 (EVEREST) trial
- Journal / Conference
- SITC Annual Meeting (Nov. 1-5, 2023, San Diego, CA), poster
- Year
- 2023
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- Study Number(s)
- S1609
Clinical outcomes and translational analysis of DART S1609: the thyroid cancer cohort; PD-1+ PD-L1+ TIL correlated with favorable survival
- Journal / Conference
- JCO Precision Oncology Sep:7:e2300197. doi: 10.1200/PO.23.00197
- Year
- 2023
- Research Committee(s)
- Breast
- PMID
- PMID37972336
- PMC
- PMC10681491
- Study Number(s)
- SWOG-9313
Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency
- Journal / Conference
- ASCO Quality Care Symposium (October 27-28, 2023, Boston, MA, poster; JCO Oncol Pract 19, 2023 (suppl 11; abstr 439)
- Year
- 2023
- Research Committee(s)
- Cancer Care Delivery
- Study Number(s)
- S2108CD
Mixed-methods analysis of physician genomic confidence in the pre-implementation phase of the cluster randomized trial evaluating genomic tumor boards (SWOG S2108CD, NCT05455606)
- Journal / Conference
- Biomarker Research Mar 16;11(1):31. doi: 10.1186/s40364-023-00461-0
- Year
- 2023
- Research Committee(s)
- Leukemia
- PMID
- PMID36927800
- PMC
- PMC10022072
- Study Number(s)
- S0106, S0112, SWOG-9031, SWOG-9333
Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients
- Journal / Conference
- Lancet Hematology Dec;10(12):e953-e954. doi: 10.1016/S2352-3026(23)00336-8
- Year
- 2023
- Research Committee(s)
- Myeloma
- PMID
- PMID38030317
- Study Number(s)
- S2209